Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II safety and immunogenicity study of Fluad 2011/2012 in elderly adults
2010-021841-38Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fluzone Trivalent in influenza, sponsored by Novartis. Primary endpoints: Safety of a single intramuscular dose of Fluad, Immunogenicity by SRH at Day 22 and 2 more. Started May 2011; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on 2010-021841-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021841-38.